PDS Biotechnology Corporation (Nasdaq: PDSB) announced the publication of results from its VERSATILE-002 phase 2 clinical trial in the September ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE